Tags

Type your tag names separated by a space and hit enter

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply.
N Engl J Med. 2020 01 02; 382(1):91.NEJM

Authors+Show Affiliations

Icahn School of Medicine at Mount Sinai, New York, NY bruce.sands@mssm.edu.Janssen Research and Development, Spring House, PA.

Pub Type(s)

Letter
Comment

Language

eng

PubMed ID

31875505

Citation

Sands, Bruce E., and Colleen Marano. "Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply." The New England Journal of Medicine, vol. 382, no. 1, 2020, p. 91.
Sands BE, Marano C. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply. N Engl J Med. 2020;382(1):91.
Sands, B. E., & Marano, C. (2020). Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply. The New England Journal of Medicine, 382(1), 91. https://doi.org/10.1056/NEJMc1915042
Sands BE, Marano C. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply. N Engl J Med. 2020 01 2;382(1):91. PubMed PMID: 31875505.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply. AU - Sands,Bruce E, AU - Marano,Colleen, PY - 2019/12/26/entrez PY - 2019/12/26/pubmed PY - 2020/1/4/medline SP - 91 EP - 91 JF - The New England journal of medicine JO - N Engl J Med VL - 382 IS - 1 SN - 1533-4406 UR - https://www.unboundmedicine.com/medline/citation/31875505/full_citation L2 - https://www.nejm.org/doi/10.1056/NEJMc1915042?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -